Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293652 | 0.85 | MEN1 (0.55) | L3MBTL1KMT2ALMNAMEN1KDM4E | |
| SCHEMBL8011431 | 0.83 | MAPT (0.45) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL27663392 | 0.83 | MAPT (0.45) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL28246353 | 0.83 | AAK1 (0.42) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL15268712 | 0.83 | SLC6A2 (0.42) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL28271058 | 0.82 | AAK1 (0.44) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL28022205 | 0.82 | AAK1 (0.44) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL2291108 | 0.82 | CTSK (0.44) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL28750863 | 0.81 | AAK1 (0.39) | AAK1CTSSCTSKATML3MBTL1 | |
| SCHEMBL1957995 | 0.81 | KMT2A (0.58) | KMT2ALMNAMEN1KDM4ECHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1648868-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | AAK1 3592/4885CTSS 42/4885CTSK 324/4885 |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | AAK1 3457/4885CTSS 81/4885CTSK 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.